Daewoong Pharmaceutical's Envlo (enavogliflozin), a first-in-class SGLT-2 inhibitor, has been approved by Ecuador's health authority, ARCSA, marking its first approval outside of South Korea.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.